JP2022527569A5 - - Google Patents

Info

Publication number
JP2022527569A5
JP2022527569A5 JP2021559455A JP2021559455A JP2022527569A5 JP 2022527569 A5 JP2022527569 A5 JP 2022527569A5 JP 2021559455 A JP2021559455 A JP 2021559455A JP 2021559455 A JP2021559455 A JP 2021559455A JP 2022527569 A5 JP2022527569 A5 JP 2022527569A5
Authority
JP
Japan
Prior art keywords
mito
linker
group
targeted ligand
ligand cluster
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021559455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527569A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/023603 external-priority patent/WO2020191183A1/en
Publication of JP2022527569A publication Critical patent/JP2022527569A/ja
Publication of JP2022527569A5 publication Critical patent/JP2022527569A5/ja
Pending legal-status Critical Current

Links

JP2021559455A 2019-03-21 2020-03-19 治療剤の標的化送達のための多価リガンドクラスター Pending JP2022527569A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962821628P 2019-03-21 2019-03-21
US62/821,628 2019-03-21
US201962952607P 2019-12-23 2019-12-23
US62/952,607 2019-12-23
PCT/US2020/023603 WO2020191183A1 (en) 2019-03-21 2020-03-19 Multivalent ligand clusters for targeted delivery of therapeutic agents

Publications (2)

Publication Number Publication Date
JP2022527569A JP2022527569A (ja) 2022-06-02
JP2022527569A5 true JP2022527569A5 (cg-RX-API-DMAC7.html) 2023-03-28

Family

ID=70285946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559455A Pending JP2022527569A (ja) 2019-03-21 2020-03-19 治療剤の標的化送達のための多価リガンドクラスター

Country Status (7)

Country Link
US (1) US20220175934A1 (cg-RX-API-DMAC7.html)
EP (1) EP3923989A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022527569A (cg-RX-API-DMAC7.html)
CN (1) CN114206389A (cg-RX-API-DMAC7.html)
AU (1) AU2020242043A1 (cg-RX-API-DMAC7.html)
CA (1) CA3133629A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020191183A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230092615A1 (en) 2020-02-21 2023-03-23 Mitotherapeutix Llc Compositions and methods for inhibiting expressing of methylation-controlled j-protein (mcj)
WO2022109398A1 (en) * 2020-11-23 2022-05-27 University Of Massachusetts Oligonucleotides for dgat2 modulation
CN115850358B (zh) * 2021-03-08 2026-04-24 南京吉迈生物技术有限公司 GalNAc簇亚磷酰胺和靶向治疗性核苷
PE20250353A1 (es) * 2021-06-24 2025-02-06 Lilly Co Eli Terapeutica con arn novedosos y usos de estos
PE20250120A1 (es) * 2021-06-24 2025-01-16 Lilly Co Eli Restos de administracion terapeutica novedosos y usos de estos
KR20240082358A (ko) * 2021-09-23 2024-06-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 치료제의 표적화된 전달을 위한 디아민 스캐폴드를 갖는 다가 리간드 클러스터
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
KR20240111795A (ko) 2021-11-29 2024-07-17 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. B형 간염 바이러스 (hbv) 단백질의 발현을 억제하기 위한 조성물 및 방법
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
WO2024104386A1 (zh) * 2022-11-16 2024-05-23 南京明德新药研发有限公司 一类含七元杂环的三齿缀合基团
CN116535449B (zh) * 2023-03-22 2025-09-16 华东理工大学 一种糖基没食子酸类衍生物及其制备方法与在制备乳腺癌靶向诊疗材料中的应用
CN116854753B (zh) * 2023-06-01 2025-12-09 北京炫景瑞医药科技有限公司 一种化合物、缀合物、组合物以及它们的用途
GB202311334D0 (en) * 2023-07-24 2023-09-06 Astrazeneca Ab Multivalent cargo-carrying complexes and uses thereof
TW202516009A (zh) 2023-10-10 2025-04-16 大陸商上海舶望製藥有限公司 抑制澱粉樣前體蛋白(app)表達的組合物和方法
WO2026159213A1 (en) * 2025-01-23 2026-07-30 Astrazeneca Ab Targeted lipid nanoparticles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
PL2992098T3 (pl) * 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
JPWO2017111137A1 (ja) * 2015-12-22 2018-10-18 味の素株式会社 オリゴヌクレオチドの製造方法
TWI859114B (zh) * 2016-04-11 2024-10-21 加拿大商艾爾布圖斯生技公司 靶向組合物
WO2017178656A1 (en) * 2016-04-14 2017-10-19 Roche Innovation Center Copenhagen A/S TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
JOP20170056B1 (ar) * 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة

Similar Documents

Publication Publication Date Title
US5449769A (en) Method and reagent for sulfurization of organophosphorous compounds
US5367066A (en) Oligonucleotides with selectably cleavable and/or abasic sites
US5536821A (en) Aminoalkylphosphorothioamidate oligonucleotide deratives
JP2022528840A5 (cg-RX-API-DMAC7.html)
JP2818650B2 (ja) トリスヒドロキシメチルエタン化合物
JP2024527542A5 (cg-RX-API-DMAC7.html)
JP5689054B2 (ja) Rna化学合成方法
JP2020522265A5 (cg-RX-API-DMAC7.html)
JP2019503394A5 (cg-RX-API-DMAC7.html)
KR20190044653A (ko) 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드
KR102375480B1 (ko) 인 보호기 및 이의 제조 방법 및 용도
CN103435672A (zh) 含有取代苄基的新型核苷磷酸酯前药的结构与合成
JPH07508042A (ja) 新規2’−0−アルキルヌクレオシドおよびホスホロアミダイトの製造法およびその使用
JPH05505178A (ja) オリゴリボヌクレオシド及びオリゴデオキシリボヌクレオシドのボラノフォスフェート
AU2001291540A1 (en) Linker phosphoramidites for oligonucleotide synthesis
JP5194256B2 (ja) 2’水酸基修飾リボヌクレオシド誘導体
JP2011088935A (ja) リン原子修飾ヌクレオチド類縁体の製造のための光学活性ヌクレオシド3’−ホスホロアミダイト
WO1990008156A1 (fr) Derives de molecules polyhydroxylees permettant l'introduction d'au moins une ramification dans un oligonucleotide
WO1992006103A1 (en) Synthesis of oligonucleotides
Yao et al. Modular Access to P (V)‐Stereogenic Compounds via Cu‐Catalyzed Desymmetrization of (Thio) Phosphonic Dichlorides
Dong et al. Catalytic construction of P-stereogenic center via phosphorus-centered nucleophilic substitution
Wang et al. Stereoselective synthesis of P-stereogenic nucleotide prodrugs and oligonucleotides
JP2008502673A5 (cg-RX-API-DMAC7.html)
CN111393243A (zh) 一种磷手性核苷类药物的合成方法及该方法得到的药物
AU642673B2 (en) Method and reagent for sulfurization of organophosphorous compounds